SIOC English
化学学报
高级检索

化学学报 >

2012 , Vol. 70 >Issue 04: 512 - 518

DOI: https://doi.org/10.6023/A1107052

研究简报

3-取代硫基-5-(2-羟基苯基)-4H-1,2,4-三唑类化合物抑菌活性的定量构效关系和结构修饰的理论研究

  • 冯长君
展开
  • 徐州工程学院化学化工学院 徐州 221111

收稿日期: 2011-07-05

  修回日期: 2012-10-31

  网络出版日期: 2011-11-23

基金资助

国家自然科学基金(No. 21075138)、徐州市科技局基金(No. XZZD1104)和贾汪区科技局基金(No. XM10A05)资助项目.

收起

Theoretical Studies on Quantitative Structure-Activity Relationship and Structural Modification for 3-Substituted Sulfur-5- (2-Hydroxyphenyl)-4H-1,2,4-Triazole Compounds

  • Feng Changjun
Expand
  • School of Chemistry & Chemical Engineering, Xuzhou Institute of Technology, Xuzhou 221111

Received date: 2011-07-05

  Revised date: 2012-10-31

  Online published: 2011-11-23

Supported by

Project supported by the National Natural Science Foundation of China (No. 21075138), the Foundation of Science and Technology Bureau of Xuzhou City (No. XZZD1104), and Foundation of Science and Technology Bureau of Jiawang County (No. XM10A05).

Fold

摘要

用DFT-B3LYP 方法, 在基组6-31G 水平, 对24 种3-取代硫基-5-(2-羟基苯基)-4H-1,2,4-三唑类化合物分子进行几何优化, 并计算了EHOMO, ELUMO, ENHOMO, ENLUMO, QC1～QC8, QN1～QN3, QO, QS和ΔE1, ΔE2, ΣQ 等量子化学描述符(qc). 通过最佳变量子集回归建立13 种上述化合物对大肠杆菌、白色念珠菌、金黄色葡萄球菌等抑菌活性(AJ: Ae, Am 和As) 的QSAR 模型. 对于大肠杆菌的Ae 模型的相关系数(R2)和逐一剔除法交叉验证系数Rcv2 依次为0.930 和0.871, 相应白色念珠菌Am 模型为0.926 和0.869, As 模型为0.781 和0.572. 通过Radj2, F, Rcv2, VIF, AIC, FIT 等检验, 上述模型具有令人满意的稳健性和预测能力. 结果显示ΔE1 和ΣQ 直接影响这些化合物的生物活性: ΣQ 增大, 其抑菌活性增强; ΔE1 越高, AJ 下降. 据此提出三唑类化合物分子可能的抑菌机理. 由此发现, 在三唑类化合物分子的R 中合适部位选用吸电子能力较强的取代基团进行结构修饰, 有利于提高被修饰后分子的抑菌活性. 根据对R 进行结构修饰(共提出11 种化合物), 得出4 种抑菌活性均超出100%的三唑类化合物(质量分数为0.01%), 希望将来得到生物实验的证实.

关键词： 3-取代硫基-5-(2-羟基苯基)-4H-1,2,4-三唑; 密度泛函理论(DFT); 量化参数; 大肠杆菌; 白色念珠菌; 金黄色葡萄球菌; 抑菌活性; 抑菌机理; 定量构效关系(QSAR)

本文引用格式

冯长君 . 3-取代硫基-5-(2-羟基苯基)-4H-1,2,4-三唑类化合物抑菌活性的定量构效关系和结构修饰的理论研究[J]. 化学学报, 2012 , 70(04) : 512 -518 . DOI: 10.6023/A1107052

Abstract

The DFT-B3LYP method, with the basis set 6-31G, was employed to calculate the molecular geometries and electronic structures of 24 3-substituted sulfur-5-(2-hydroxyphenyl)-4H-1,2,4-triazole compounds. EHOMO, ELUMO, ENHOMO, ENLUMO, QC1～QC8, QN1～QN3, QO, QS, ΔE1, ΔE2, ΣQ were selected as quantum chemical descriptors (qc). The quantitative structure-activity relationships (QSAR) were established by using leaps-and-bounds regression analysis for the antibacterial activities (AJ: Am, Ae and As) of 13 compounds to Escherichia coli, Monilia albican and Staphylococcus aureus along with the qc. The correlation coefficients (R2) and the leave-one-out (LOO) cross validation Rcv2 for the Ae, Am and As models were 0.930 and 0.871; 0.926 and 0.869; 0.781 and 0.572 respectively. The QSAR models have both favorable estimation stability and good prediction capability by Aadj2, F, Rcv2, VIF, AIC, FIT tests. The results indicate that the ΔE1 and ΣQ are main factors which can affect the bioactivities of these compounds directly. The antibacterial activities of the compounds increase with the increase of the ΣQ; however the higher the ΔA1 is, the lower the AJ is. The possible mechanism has been given for the antibacterial of the triazole compounds. It is known that the suitable structural modifications of R group in triazole compounds with the strong electron- attracting one are beneficial to the antibacterial activities. According to the results (11 compounds) obtained from the structural modifications, the antibacterial activities of four modified molecules are over 100% when mass fraction is 0.01%, and it is expected to be confirmed by using biologic experiments.

Key words： 3-substituted sulfur-5-(2-hydroxyphenyl)-4H-1,2,4-triazole; density functional theory (DFT); quantum chemical descriptor; Escherichia coli; Monilia albican; Staphylococcus aureus; antibacterial activity; antibacterial mechanism; quantitative structure-activity relationship (QSAR)

参考文献

1 Feng, C.-J. Acta Phys.-Chim. Sin. 2010, 26, 193 (in Chinese). (冯长君, 物理化学学报, 2010, 26, 193.)

2 Feng, C.-J.; Yang, W.-H.; Mu, L.-L; Cai, K.-Y. Acta Chim. Sinica 2008, 66, 2093 (in Chinese). (冯长君, 沐来龙, 杨伟华, 蔡可迎, 化学学报, 2008, 66, 2093.)

3 Nanbo, A.; Nanbo, T. Quant. Struct.-Act. Relat. 2002, 21, 613.  

4 Xie, H.-J.; Lei, Q.-F.; Hu, X.-H.; Xuan, G.-D.; Fang, W.-J. Acta Chim. Sinica 2011, 69, 399 (in Chinese). (谢湖均, 雷群芳, 胡晓环, 宣贵达, 方文军, 化学学报, 2011, 69, 399.)

5 Bai, X.; Zhou, C.-H.; Mi, J.-L. Chem. Res. Appl. 2007, 19, 721 (in Chinese). (白雪, 周成合, 米佳丽, 化学研究与应用, 2007, 19, 721.)

6 Sun, X.-H.; Bai, Y.; Liu, Y.-F.; Chen, B. Acta Chim. Sinica 2010, 68, 788 (in Chinese). (孙晓红, 白燕, 刘源发, 陈邦, 化学学报, 2010, 68, 788.)

7 Yang, S.-H.; Zhai, Z.-W.; Xu, L.-Z. Agrochemicals 2010, 49, 645 (in Chinese). (杨双花, 翟智卫, 许良忠, 农药, 2010, 49, 645.)

8 Zhu, S.-S.; Lu, J.-R.; Xin, C.-W.; Lu, B.-W.; Bao, X.-R.; Zou, M.; Liu, Q. Chem. J. Chin. Univ. 2010, 31, 2228 (in Chinese). (朱姗姗, 卢俊瑞, 辛春伟, 卢博为, 鲍秀荣, 邹敏, 刘倩, 高等学校化学学报, 2010, 31, 2228.)

9 Wang, X.-D.; Lin, Z.-F.; Yin, D.-Q.; Liu, S.-S.; Wang, L.-S. Sci. China, Ser. B-Chem. 2005, 48, 246.  

10 Zhang, L.; Wan, J.; Yang, G.-F. Bioorg. Med. Chem. 2004, 12, 6183.  

11 Wan, J.; Zhang, L.; Yang, G.-F. J. Comput. Chem. 2004, 25, 1827.  

12 Douglas, M. H.; Subhash, C. B.; Denise, M. J. Chem. Inf. Comput. Sci. 2003, 43, 579.  

13 Clark, M.; Cramer, R. D. Quant. Struct.-Act. Relat. 1993, 12, 137.  

14 Wei, D.-B.; Zhang, A.-Q.; Wu, C.-D.; Han, S.-K.; Wang, L.-S. Chemosphere 2001, 44, 1421.  

15 Urra, L. S.; Gonza′lez, M. P.; Teijeira, M. Bioorg. Med. Chem. 2006, 14, 7347.  

16 Urra, L. S.; Gonza′lez, M. P.; Teijeira, M. Bioorg. Med. Chem. 2007, 15, 3565.  

17 Zhang, W.-N. Modern Drug Design, China Medical Science and Technology Press, Beijing, 2006, p. 145 (in Chinese). (张万年, 现代药物设计学, 中国医药科技出版社, 北京, 2006, p. 145.)

18 Guo, Z.-R. Molecular Drug Design, Science Press, Beijing, 2005, p. 485 (in Chinese). (郭宗儒, 药物分子设计, 科学出版社, 北京, 2005, p. 485.)
Options
文章导航

/

〈 〉